Watch as Dr David Bunka, Aptamer Group CTO, details how BLI is used within Aptamer Group’s screening and validation processes to identify the best aptamer and Optimer™ reagents, with…
A newly published paper in The Analyst by Dr. Federico Polo, Assistant Professor at Ca’ Foscari University of Venice and former group leader at the National…
SARS-CoV-2 was first identified in November 2019 in Wuhan, China. Spreading quickly across the globe, COVID-19, the disease caused by SARS_CoV-2, was announced as a pandemic just four months…
The COVID-19 pandemic has presented significant challenges to the biopharmaceutical industry, requiring rapid identification and development of SARS-CoV-2 affinity reagents for research, diagnostics, and therapeutics. Our application note details how…
Although amyloid fibrils assembled in vitro commonly involve a single protein, fibrils formed in vivo can contain multiple protein sequences. The amyloidogenic protein human β2-microglobulin (hβ2m) can co-polymerize with its N-terminally truncated variant…
Aptamer mediated Hot start PCR to detect MERS-CoV Polymerase chain reaction (PCR) is an established method to amplify specific fragments of DNA, for applications such as…
